MedPath

A Real-World Study of JT001 for COVID-19

Active, not recruiting
Conditions
COVID-19
Registration Number
NCT06142201
Lead Sponsor
Shanghai Vinnerna Biosciences Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Active, not recruiting
Sex
All
Target Recruitment
7656
Inclusion Criteria

Inclusion Criteria:<br><br> 1. Age =18 years old.<br><br> 2. The novel coronavirus infection (COVID-19) meets at least one of the following five<br> criteria:<br><br> 1) Diagnosis of novel coronavirus infection; 2) Diagnosed with novel coronavirus<br> pneumonia; 3) The novel coronavirus nucleic acid test is positive; 4) Test positive<br> for novel coronavirus antigen; 5) Culture positive for novel coronavirus.<br><br> 3. Patients who have not developed severe COVID-19 or died within 28 days of COVID-19<br> diagnosis, or who have developed severe COVID-19 or died within 28 days of COVID-19<br> diagnosis, were treated with deuterimodivir hydrobromide tablets or were not treated<br> with anti-novel coronavirus before disease progression.<br><br>Exclusion Criteria:<br><br>· Patients who have not developed severe COVID-19 or died within 28 days of COVID-19<br>diagnosis, or those who have developed severe COVID-19 or died within 28 days of COVID-19<br>diagnosis, received the following anti-novel coronavirus treatments before disease<br>progression, including: Nematavir tablet/Ritonavir tablet, Azvudine tablet, Monoravir<br>capsule, Zenotavir tablet/Ritonavir tablet, Leritvir tablet, Ambavirzumab/Romisivir<br>injection, human immunoglobulin for COVID-19 or convalescent plasma for COVID-19<br>survivors.

Exclusion Criteria

Not provided

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of COVID-19 disease progression (severe COVID-19 or all-cause death) by day 28
Secondary Outcome Measures
NameTimeMethod
Incidence of the following COVID-19 disease progression events by day 28;Incidence of severe Covid-19-related events up to day 28;The incidence of all aes and abnormal laboratory changes on day 28, etc
© Copyright 2025. All Rights Reserved by MedPath